




FIG. 1A

20X Objective						10X Objective				
	Setting 1	Setting 2	Setting 3	Setting 4	Setting 5	Setting 6	Setting 7	Setting 8	Setting 9	Setting 10
Power (mW)	2.701	4.755	8.588	11.73	15.96	5.631	9.527	13.58	18.44	34.35
Intensity (mW/cm²)	203.79	358.77	647.98	885.04	1204.20	86.04	145.56	207.49	281.74	524.98

FIG. 1B




FIG. 1C




FIG. 2A

20X Objective				10X Objective			
	Setting 1	Setting 2	Setting 3	Setting 4	Setting 5	Setting 6	Setting 7
Power (mW)	0.51	1.37	2.00	4.11	0.45	1.17	6.95
Intensity (mW/cm ²)	38.48	103.37	150.90	310.10	6.88	17.88	106.19

FIG. 2B




FIG. 2C

5/49




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 4C

7/49




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8




FIG. 9

Specificity Assay





FIG. 10

13/49

Antigen Presenting Cell Assay**FIG. 11**




FIG. 12A




FIG. 12B

16/49

Brightfield




FIG. 13A

Fluorescence




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C





FIG. 14D

19/49

**FIG. 14E**




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D

22/49




FIG. 15E







FIG. 15F





25/49




FIG. 16E




FIG. 16F

26/49




FIG. 17

27/49




FIG. 18





FIG. 19A

29/49



All NL 1 containing reads: Drug compound (DBC) linked to modulation of Signaling Pathway and/or Secreted Products from Cell of Interest

Screen for Signaling Pathway transcript fraction or number changes
 different from baseline (optionally normalized by housekeeping gene transcripts)
 AND/OR Screen for Secretion Sequence 1 fraction or number changes
 different from baseline (optionally normalized by baseline secretion or transcript)

1. Identify all Drug compounds associated with modulated Signaling Pathway AND/OR modulated Secretion using linked NL #
2. Rank potency by quantitative strength of effect on Signaling Pathway modulation AND/OR Secretion modulation

FIG. 19B

30/49




FIG. 20A

31/49




FIG. 20B

32/49




FIG. 20C

33/49




FIG. 20D

34/49




FIG. 21

35/49




FIG. 22

36/49




FIG. 23




FIG. 24A

Non-Emulsified Samples




FIG. 24B

39/49




FIG. 25

FIG. 26A






FIG. 26B



41/49

Nanovials Loaded into Droplets with GEM Beads
using 10X chromium instrument




FIG. 27

35 Micron Nanovials Injected in Chromium Chip G




FIG. 28A

60 Micron Nanovials Injected in Chromium Chip G




FIG. 28B

43/49




FIG. 29A




FIG. 29B

45/49

2 Cell Loading Data




FIG. 30

46/49






FIG. 31

47/49

$$Purity = \frac{N_{Pos}}{N_{Pos} + N_{Neg}} \times 100\%$$



$$Enrichment = \frac{N_{Pos,Post}/N_{Neg,Post}}{N_{Pos,Pre}/N_{Neg,Pre}}$$



$$Yield = \frac{N_{Pos,Post}}{N_{Pre,Pre}} \times 100\%$$




FIG. 32




FIG. 33

49/49




FIG. 34